Tag: ESMO 2019
ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression
The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor regression in preclinical models of...
Phase I/IIa Trial Evaluating BT1718 Shows Encouraging Progress in Dose Escalation...
Updated data from a Phase I/IIa trial evaluating BT1718, a Bicycle Toxin Conjugate being developed Bicycle Therapeutics, was presented during a poster session (Abstract...